Celliaz
Cambridge, United States· Est.
Celliaz develops protein‑based therapeutics to regenerate retinal tissue and restore vision in degenerative eye diseases.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Celliaz develops protein‑based therapeutics to regenerate retinal tissue and restore vision in degenerative eye diseases.
OphthalmologyRetinal Degeneration
Technology Platform
Engineering of recombinant proteins and antibody fragments that harness homeodomain transcription factor signaling to promote retinal cell regeneration and functional vision restoration.
Opportunities
Large unmet need in retinal degeneration and a market eager for regenerative therapies; potential for strategic alliances with ophthalmology leaders.
Risk Factors
Scientific translation from animal models to humans, ocular delivery challenges, and financing risk for advancing to clinical trials.
Competitive Landscape
Competes with gene‑therapy and cell‑therapy approaches; differentiation lies in protein/antibody‑based regeneration, offering potentially simpler manufacturing and dosing.